Correspondence | Published:

Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Klyuchnikov E, von Pein UM, Ayuk FA, Christopeit M, Adjalle R, van Randenborgh A, et al. Daratumumab is an effective and safe salvage therapy in relapsed/refractory patients with multiple myeloma after allogeneic stem cell transplantation. Blood. 2016;128:3437.

  2. 2.

    Krishnan A, Parameswaran H, Chhabra S, Biran N, Stiller T, Htut M, et al. Incidence and timing of graft versus host disease (GVHD) after daratumumab (Dara) anti CD38 therapy post allogeneic transplant (alloHCT) for myeloma. Clin Lymphoma Myeloma Leuk. 2017;17:e71.

  3. 3.

    Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–60. https://doi.org/10.1016/S0140-6736(15)01120-4.

  4. 4.

    Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H. Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol. 2018;101:699–702. https://doi.org/10.1111/ejh.13164.

  5. 5.

    Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N. Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk. 2019;19:e9–e11. https://doi.org/10.1016/j.clml.2018.10.002.

Download references

Acknowledgments

This study was supported in part by the Spanish grant of Instituto de Salud Carlos III (PI16/01485) and FEDER European Union.

Author information

Correspondence to Ana Pilar Gonzalez-Rodriguez.

Ethics declarations

Conflict of interest

APG-R has served as speaker and member of advisory boards from Janssen and Celgene and Takeda. MVM has served as speaker and member of advisory boards from Janssen, Amgen, Celgene, Takeda, GSK, Abbvie, EDO, and Pharmamar. LR has served as speaker and member of advisory boards from Janssen, Amgen, Celgene, and Takeda. MAH has served as speaker and member of advisory boards from Janssen, Amgen, Celgene, and Takeda. LLC, DFM, AJG-H, PP, AB, TZR, PSD, SG-M, JZ, AJU, FdeA, CS-B, AL-S, and SG declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1